fda bpc-157 compounding category 2 list Approval Status 2026: Clinical Trials FDA has removed certain bulk

FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Category 1 vs. Category 2. The FDA's peptide update, explained. Category 2 peptides are on the FDA's difficult to compound list, which effectively blocks licensed pharmacies from producing them. Category 1 means BPC 157 just got voted in favor to be added to the 503A Bulk Drug Substances list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank FDA Removes Peptides from Category 2 List, Paving Way for Regulation Jonathan Cole posted on the topic LinkedIn

SKU: 32973644443 · From equiscorp.hu